Capital One analyst Tim Chiang initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $7.
Capital One Initiates Coverage On Jasper Therapeutics With Overweight Rating, Announces Price Target of $7
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.